ガン治療のためのインスリン類似成長因子中和抗体
1Cancer Centre, Institute of Translational Medicine, Faculty of Health Sciences, University of Macau, Macau SAR 999078, China.
Journal of leukocyte biology
|August 21, 2025
まとめ
インスリン類似成長因子 (IGFs) を標的とする新しい抗体療法では,ガンにおけるIGF-1受容体 (IGF-1R) 治療に対する耐性を克服する見通しを示している. これらの新しいアプローチは 臨床試験に進んでおり 治療戦略の改善に希望を与えています
科学分野:
- 腫瘍学
- 分子生物学
- 免疫療法
背景:
- インスリン類似成長因子 (IGF) 軸は細胞の成長,生存,分化に重要な役割を果たします.
- IGF- 1受容体 (IGF- 1R) を標的とする治療は,単独療法として限られた有効性を示しています.
- 異常なIGF- IおよびIGF- II発現は,IGF- 1Rを標的とする治療に対する耐性を促進する.
研究 の 目的:
- IGF-Iおよび/またはIGF-IIに対する抗体を中和する最近の進歩をレビューする.
- がん治療の新たな抗体ベースの戦略を探求する.
- 治療抵抗性の克服のための組み合わせ療法の可能性を議論する.
主な方法:
- IGF- IおよびIGF- II中和抗体に関する臨床前および早期臨床データのレビュー
- モノクローナル抗体,バイスペシフィック抗体,エンジニアリングされた抗体ドメインを含む様々な抗体形式の分析.
- IGF軸シグナリングの文脈における抵抗メカニズムの検討.
主要な成果:
- IGF- Iおよび/またはIGF- IIに対する中和抗体は,臨床前がんモデルにおいて有意な治療の可能性を示しています.
- これらの抗体ベースのアプローチは,現在初期段階の臨床試験で調査中です.
- 双特異抗体と人工抗体ドメインの開発により,標的化能力が向上する.
結論:
- 抗体によるIGF-IとIGF-IIの中和は,がん治療の有効性を高める有望な戦略です.
- IGF-1Rを標的とする治療法に対する耐性を克服するには,IGFリガンドを標的とする必要があります.
- 将来の研究は,IGF軸を標的とする抗体を含む組み合わせ戦略の最適化に焦点を当てるべきである.
関連する概念動画
01:27Tumor Immunotherapy
660
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
660
02:57Targeted Cancer Therapies
7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.8K
02:38Mitogens and the Cell Cycle
6.6K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.6K
02:50Combination Therapies and Personalized Medicine
5.1K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.1K
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
231
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
231